NCT07681219Not yet recruiting
LRRK2 (Leucine-Rich Repeat Kinase 2) Parkinson's Disease Fingerprint
LRRK2 Associated Parkinson's Disease: Definition of a Clinical, Molecular and Neurophysiological Fingerprint
Source: ClinicalTrials.gov · Last updated 10 Jul 2026
Brief summary (registry, in English)
The goal of this interventional monocentric study is to identify molecular and clinical markers of LRRK2-related Parkinson's disease through blood markers analysis and deep clinical phenotyping. Patients who meet the inclusion criteria, after signing the informed consent form will be clinically evaluated by a neurologist expert in movement disorders. Eventually, patients will undergo a blood sample collection, a brain MRI, and a high density EEG. All data will be collected using an ad hoc electronic Case Report Form (CRF) developed for the study
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 26 Jun 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 1 Sept 2029
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Diseases
- Parkinson disease
- NCT number
- NCT07681219
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 1 Sept 2026 to the primary completion date, 1 Sept 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- active infectious disease or history within the previous 4 weeks,
- continuative therapy (at least 1 week) with NSAIDs or steroids within the previous 12 weeks,
- active malignancy, autoinflammatory or autoimmune diseases or history within the previous 3 years;
- alcohol or drug abuse or dependence
Other illness
- Active or history of other neurological disorders,
Other
- any contraindication to the execution of the MRI (including claustrophobia).
Who the study is looking for
- age 30-80 years,
- clinically established diagnosis of PD according to the Movement Disorders Society (MDS) diagnostic criteria,
- Hoehn \& Yahr (H\&Y) stage between 1 and 3,
- 10 patients with a LRRK2 associated parkinsonism and 10 with sporadic PD tested with a NGS panel and MLPA for PD associated genes,
- ability to provide informed consent.
Age in the registry: 30 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.